Hasil Pencarian - Masao Nakata

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad

    Tofacitinib overcomes an IFNγ‐induced decrease in NK cell‐mediated cytotoxicity via the regulation of immune‐related molecules in LC‐2/ad oleh Riki Okita, Katsuhiko Shimizu, Yuji Nojima, Shinsuke Saisho, Masao Nakata

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.

    Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in... oleh Riki Okita, Diana Wolf, Koichiro Yasuda, Ai Maeda, Takuro Yukawa, Shinsuke Saisho, Katsuhiko Shimizu, Yoshiyuki Yamaguchi, Mikio Oka, Eiichi Nakayama, Andreas Lundqvist, Rolf Kiessling, Barbara Seliger, Masao Nakata

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

    Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setou... oleh Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Hiroshige Nakamura, Makoto Sonobe, Takuji Fujinaga, Kazuhiko Kataoka, Kenichi Gemba, Masafumi Kataoka, Katsuyuki Hotta, Hiroshige Yoshioka, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer

    Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer oleh Kanako Sakaeda, Koji Kurose, Yuki Matsumura, Satoshi Muto, Minoru Fukuda, Nanae Sugasaki, Masaaki Fukuda, Shinnosuke Takemoto, Hirokazu Taniguchi, Takeshi Masuda, Katsuhiko Shimizu, Yuki Kataoka, Yasuhiro Irino, Yumiko Sakai, Yusuke Atarashi, Masatoshi Yanagida, Noboru Hattori, Hiroshi Mukae, Masao Nakata, Eiichiro Kanda, Toru Oga, Hiroyuki Suzuki, Mikio Oka

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.

    Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA... oleh Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Kenichi Gemba, Isao Sano, Takuji Fujinaga, Masafumi Kataoka, Yasuhiro Terazaki, Nobukazu Fujimoto, Kazuhiko Kataoka, Shinji Kosaka, Motohiro Yamashita, Hidetoshi Inokawa, Masaaki Inoue, Hiroshige Nakamura, Yoshinori Yamashita, Katsuyuki Hotta, Hiroshige Yoshioka, Satoshi Morita, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: